RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $117

Benzinga Newsdesk www.benzinga.com Negative 91.7%

Neg 91.7% Neu 0% Pos 0%

RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $119 to $117.